Results 31 to 40 of about 4,658,313 (257)

Exploring Diversity of COVID‑19 Based on Substitution Distance.

Infection and drug resistance, 2020
The number of COVID-19 infections worldwide has reached 10 million. COVID‑19 caused by SARS-CoV-2 is more contagious than SARS-CoV-1. There is a dispute about the origin of COVID-19. Study results showed that all SARS-CoV-2 sequences around the world share a common ancestor towards the end of 2019.Virus sequences from COVID-19 samples at the early time
Chen,Yi-Hau, Wang,Hsiuying
openaire   +3 more sources

Moving from rhetoric to action: how Africa can use scientific evidence to halt the COVID-19 pandemic

Infectious Diseases of Poverty, 2020
The ongoing pandemic of the coronavirus disease 2019 has spread rapidly to all countries of the world. Africa is particularly predisposed to an escalation of the pandemic and its negative impact given its weak economy and health systems.
Olushayo Oluseun Olu, Joy Luba Lomole Waya, Sylvester Maleghemi, John Rumunu, David Ameh, Joseph Francis Wamala   +5 more
doaj   +1 more source

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

, 2021
BACKGROUND: Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19. METHODS: We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 ...
DiCioccio, A. Thomas, Saggar, Suraj, Sivapalasingam, Sumathi, Aberg, Judith A., Kampman, Wendy, Ferreira, Manuel A., Kosmicki, Jack A., Parrino, Jani, Boyapati, Anita, Criner, Gerard, Hosain, Romana, Labriola-Tompkins, Emily, Akinlade, Bolanle, Brown, Samuel M., Weinreich, David M., Bhore, Rafia, Ng Gong, Michelle, Horowitz, Julie E., Hajizadeh, Negin, Sobieszczyk, Magdalena E., Park, William, Gulabani, Daya, Yancopoulos, George D., Mahmood, Adnan, Lederer, David J., Sperber, Steven J., Musser, Bret, Stein, David K., Baras, Aris, Giannelou, Angeliki, Menon, Vidya, Somersan-Karakaya, Selin, O’Brien, Meagan, Purcell, Lisa A., Nivens, Michael C., Herman, Gary, Kowal, Bari, Waldron, Alpana, Braunstein, Ned, Ramesh, Divya   +39 more
core   +1 more source

Critical appraisal in rapid systematic reviews of COVID-19 studies: implementation of the Quality Criteria Checklist (QCC)

Systematic Reviews, 2023
In this letter, we briefly describe how we selected and implemented the quality criteria checklist (QCC) as a critical appraisal tool in rapid systematic reviews conducted to inform public health advice, guidance and policy during the COVID-19 pandemic ...
Daphne Duval, Nicola Pearce-Smith, Jennifer C. Palmer, Jason Kwasi Sarfo-Annin, Paul Rudd, Rachel Clark   +5 more
doaj   +1 more source

The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea [PDF]

Osong Public Health and Research Perspectives
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination.
Na-Young Jeong, Hyesook Park, Sanghoon Oh, Seung Eun Jung, Dong-Hyun Kim, Hyoung-Shik Shin, Hee Chul Han, Jong-Koo Lee, Jun Hee Woo, Jaehun Jung, Joongyub Lee, Ju-Young Shin, Sun-Young Jung, Byung-Joo Park, Nam-Kyong Choi   +14 more
doaj   +1 more source

Evaluation of self-administered antigen testing in a college setting

Virology Journal, 2022
Background The objective of our investigation was to better understand barriers to implementation of self-administered antigen screening testing for SARS-CoV-2 at institutions of higher education (IHE).
Sarah C. Tinker, Jessica L. Prince-Guerra, Kelly Vermandere, Jenna Gettings, Cherie Drenzik, Gary Voccio, Tonia Parrott, Jan Drobeniuc, Tonya Hayden, Stephen Briggs, Debbie Heida, Natalie Thornburg, Lisa C. Barrios, John C. Neatherlin, Sabrina Madni, Catherine N. Rasberry, Kenneth D. Swanson, Azaibi Tamin, Jennifer L. Harcourt, Sandra Lester, Lydia Atherton, Margaret A. Honein   +21 more
doaj   +1 more source

Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future

Inflammation and Regeneration, 2020
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in Wuhan, China, and has spread globally to most countries. In Japan, the first COVID-19 patient was identified on January 15, 2020.
Tokio Hoshina, Hiroka Aonuma, Manabu Ote, Tatsuya Sakurai, Erisha Saiki, Yuki Kinjo, Kazuhiro Kondo, Masataka Okabe, Hirotaka Kanuka   +8 more
doaj   +1 more source

COVID-19 Disease and Vaccination: Knowledge, Fears, Perceptions and Feelings of Regret for Not Having Been Vaccinated among Hospitalized Greek Patients Suffering SARS-CoV-2 Infection

Infectious Disease Reports, 2022
Background: The development of vaccines against COVID-19 has greatly altered the natural course of this infection, reducing the disease’s severity and patients’ hospitalization. However, hesitancy against vaccination remains an obstacle in the attempt to
Petros Ioannou, Sotiris Tzalis, Eirini Pasparaki, Despoina Spentzouri, Myrto Konidaki, Ioanna Papakitsou, Nikolaos Spernovasilis, Nikolaos Papanikolaou, George Samonis, Diamantis P. Kofteridis   +9 more
doaj   +1 more source

Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model

BMC Public Health, 2022
Background Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity.
Phillip P. Salvatore, Melisa M. Shah, Laura Ford, Augustina Delaney, Christopher H. Hsu, Jacqueline E. Tate, Hannah L. Kirking   +6 more
doaj   +1 more source

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

, 2022
BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized,
Boulware, David R., Stewart, Thomas G., Adam, Stacey J., Castro, Mario, Lindsell, Christopher J., Hanna, George, Ruiz-Unger, Juan, Singh, Upinder, Gentile|, Hernandez, Adrian F., Wilder, Rhonda, Thicklin, Florence, McTigue, Kathleen, Ginde, Adit A., Bramante, Carolyn, DeLong, Allison, Felker, G. Michael, Dolor, Rowena J., McCarthy, Matthew W., Wilson, Sybil, Sulkowski, Mark, Collins, Sean, Dunsmore, Sarah E., Jayaweera, Dushyantha, Remaly, April, Gentile, Nina, Naggie, Susanna, Shenkman, Elizabeth   +27 more
core   +1 more source